{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:19:02Z","timestamp":1783480742647,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.prro.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T06:33:00Z","timestamp":1720938780000},"page":"e470-e479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Pilot Trial of Proton-Based Cardiac Sparing Accelerated Fractionated Radiation Therapy in Unresectable Non-small Cell Lung Cancer With Extended Durvalumab Therapy (PARTICLE-D)"],"prefix":"10.1016","volume":"14","author":[{"given":"Debora S.","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carley","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Shamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rindeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Machtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8253-2876","authenticated-orcid":false,"given":"Tithi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2024.06.007_bib0001","unstructured":"National Cancer Institute. Cancer stat facts: Lung and bronchus cancer. Accessed March 31, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html"},{"key":"10.1016\/j.prro.2024.06.007_bib0002","unstructured":"American Cancer Society. Cancer facts & figures 2022. Accessed September 18, 2023. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2022.html"},{"key":"10.1016\/j.prro.2024.06.007_bib0003","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 4.2023: Non-small cell lung cancer. Accessed October 2, 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"10.1016\/j.prro.2024.06.007_bib0004","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in Stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.prro.2024.06.007_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.radonc.2015.05.014","article-title":"Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer","volume":"115","author":"Nguyen","year":"2015","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.prro.2024.06.007_bib0006","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.adro.2019.08.001","article-title":"Early outcomes of patients with locally advanced non-small cell lung cancer treated with intensity-modulated proton therapy versus intensity-modulated radiation therapy: The Mayo Clinic experience","volume":"5","author":"Yu","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2032","article-title":"Proton beam radiotherapy and concurrent chemotherapy for unresectable Stage III non-small cell lung cancer: Final results of a phase 2 study","volume":"3","author":"Chang","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.prro.2024.06.007_bib0008","doi-asserted-by":"crossref","first-page":"dju164","DOI":"10.1093\/jnci\/dju164","article-title":"Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG Br.25","volume":"106","author":"Cheung","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2024.06.007_bib0009","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/curroncol30030239","article-title":"Stage III non-small-cell lung cancer: An overview of treatment options","volume":"30","author":"Petrella","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0010","doi-asserted-by":"crossref","first-page":"e28499","DOI":"10.4161\/onci.28499","article-title":"Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression","volume":"3","author":"Deng","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.prro.2024.06.007_bib0011","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.prro.2024.06.007_bib0012","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: Immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.prro.2024.06.007_bib0013","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.prro.2024.06.007_bib0014","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","article-title":"Probable inference, the law of succession, and statistical inference","volume":"22","author":"Wilson","year":"1927","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.prro.2024.06.007_bib0015","unstructured":"US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Accessed September 18, 2023.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"10.1016\/j.prro.2024.06.007_bib0016","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0017","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0018","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable Stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0019","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2006.01.052","article-title":"Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer","volume":"65","author":"Chang","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.007_bib0020","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2024.06.007_bib0021","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0022","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijrobp.2022.01.012","article-title":"Phase I study of accelerated hypofractionated proton therapy and chemotherapy for locally advanced non-small cell lung cancer","volume":"113","author":"Contreras","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.007_bib0023","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijrobp.2020.03.015","article-title":"Hypofractionated proton therapy with concurrent chemotherapy for locally advanced non-small cell lung cancer: A phase 1 trial from the University of Florida and proton collaborative group","volume":"107","author":"Hoppe","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl 3","key":"10.1016\/j.prro.2024.06.007_bib0024","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.seminoncol.2005.03.004","article-title":"Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer","volume":"32","author":"Machtay","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12885-016-2314-1","article-title":"Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy\/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: Preliminary results of an early terminated phase II trial","volume":"16","author":"Ren","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2024.06.007_bib0026","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijrobp.2013.03.035","article-title":"Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer","volume":"86","author":"Gomez","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2024.06.007_bib0027","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0028","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtho.2020.10.013","article-title":"Toxicity and survival after intensity-modulated proton therapy versus passive scattering proton therapy for NSCLC","volume":"16","author":"Gjyshi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0029","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jamaoncol.2021.3186","article-title":"Accelerated hypofractionated image-guided vs conventional radiotherapy for patients with stage II\/III non-small cell lung cancer and poor performance status: A randomized clinical trial","volume":"7","author":"Iyengar","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.adro.2018.05.001","article-title":"Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition","volume":"3","author":"von Reibnitz","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2024.06.007_bib0031","first-page":"1","article-title":"Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2","volume":"9","author":"Bradley","year":"2024","journal-title":"Ann Oncol."}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024001504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850024001504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:32:22Z","timestamp":1746189142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850024001504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1879850024001504"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2024.06.007","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pilot Trial of Proton-Based Cardiac Sparing Accelerated Fractionated Radiation Therapy in Unresectable Non-small Cell Lung Cancer With Extended Durvalumab Therapy (PARTICLE-D)","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}